Shree Ganesh Remedies Limited Q2 FY26 Concall Decoded: – 31% margins in generics, Europe slow, Japan dreaming big
1. Opening Hook
Shree Ganesh Remedies walked into Q2 FY26 saying, “Yes, revenue is down YoY… but have you seen our margins?”
In a year when Europe is sulking, APIs are unloved, and generic pharma is supposedly a commodity hellhole, SGRL calmly posted ~32% EBITDA margins and told investors this year is just a “consolidation phase.”
Management sounded almost bored explaining why growth is lumpy, approvals are slow, inventories are bloated, and FY27 will magically look better—trust the chemistry.
Between Japanese specialty chemicals, agro projects peaking in 2029, and innovators knocking three years early before patents expire, SGRL is clearly playing the long game.
The catch? Revenue isn’t growing yet, Europe is still 60% of sales, and FY26 guidance is basically “same as last year.”
Read on—because behind the calm tone lies a very deliberate, high-risk, high-margin strategy.
2. At a Glance
Revenue ₹30.3 cr: QoQ up 23%, because Q2 likes showing off
YoY revenue down 6%: Europe sneezed, numbers caught a cold
EBITDA ₹9.6 cr: Margins flexing at 31.7% like it’s nothing
PAT ₹4.9 cr: QoQ jump of 43%, YoY still sulking
H1 EBITDA margin 30.8%: Generics, but make it premium
FY26 guidance: Flat revenue, high patience required
3. Management’s Key Commentary
“This year is all about consolidation and capability building.” (Translation: growth please come back in FY27 😏)
“Our business inherently has lumpiness.” (Blame chemistry, approvals, customers, and timelines)
“Block 8 utilization will reach 50–60% by year-end.” (New assets warming up, slowly)
“Block 7 will be commercialized in H2 FY27.” (Still a long walk, wear patience shoes)
“Europe remains soft due to inventory planning and energy issues.” (Europe doing Europe things again)
“Japan specialty chemicals approval expected by mid-2026.” (Long courtship, high expectations 🇯🇵)
“We go backward up to six steps in chemistry.” (Margins don’t come for free 😎)
